UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa
- The P-III studies (BE HEARD I & II) evaluating bimekizumab (320mg, q2w & q4w) vs PBO in 505 & 509 patients over the 16wk. initial & 32wk. maintenance treatment periods
- The results showed that the patients treated with bimekizumab (q2w) achieved HiSCR50 in (BE HEARD I & II) trials (47.8% vs 28.7%) & (52.0% vs 32.2%) @16wk. while in q4w (45.3% vs 28.7%) & (53.8% vs 32.2%), respectively, deep levels of clinical response with a greater proportion achieved HiSCR75
- Improved health-related QoL, clinical responses (HiSCR50 & HiSCR75) were maintained with continuous treatment, 75% & 55% achieved HiSCR50 & HiSCR75 @48wk. & the safety profile was consistent with prior studies with no new safety signals. The company will submit global regulatory applications for bimekizumab in Q3’23
Ref: PRNewswire | Image: UCB
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
